首页>
外国专利>
CES: a chemoendocrine index based on PAM50 for breast cancer with positive hormone receptors with an intermediate risk of recurrence
CES: a chemoendocrine index based on PAM50 for breast cancer with positive hormone receptors with an intermediate risk of recurrence
展开▼
机译:CES:基于PAM50的化学内分泌指数,用于激素受体阳性,复发风险中等的乳腺癌
展开▼
页面导航
摘要
著录项
相似文献
摘要
The present invention refers to the development of a Chemo Endocrine Score (CES), based on the well-known PAM50 assay, for predicting whether a breast cancer patient is responsive to a chemotherapy or endocrine treatment, particularly in an HR+/HER2- breast patient beyond PAM50 Risk of Relapse (ROR) and intrinsic subtypes. Particularly, the clinical utility of this CES predictor lies in the PAM50 ROR-intermediate group, where the proportion of each CES group (endocrine-sensitive, intermediate and chemo-sensitive) is more than 25%.
展开▼